Rigel Pharmaceuticals (RIGL) Change in Account Payables (2010 - 2026)

Rigel Pharmaceuticals' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$2.7 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 539.84% year-over-year to -$2.7 million; the TTM figure through Mar 2026 stood at $532000.0 (up 110.0% YoY), while the FY2025 annual figure was $3.9 million, up 201.29% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$2.7 million, down from $3.3 million in the prior quarter.
• The five-year high for Change in Account Payables was $4.8 million in Q4 2022, with the low at -$3.4 million in Q3 2025.
• The 5-year median for Change in Account Payables is -$476000.0 (2024), against an average of $45058.8.
• The sharpest annual moves came in 2025 and 2026: Change in Account Payables surged 802.73% in 2025, then plunged 539.84% in 2026.
• Rigel Pharmaceuticals' Change in Account Payables stood at $4.8 million in 2022, then tumbled by 117.9% to -$857000.0 in 2023, then surged by 44.46% to -$476000.0 in 2024, then soared by 802.73% to $3.3 million in 2025, then plunged by 180.87% to -$2.7 million in 2026.
• Business Quant data shows RIGL's Change in Account Payables at -$2.7 million in Q1 2026, $3.3 million in Q4 2025, and -$3.4 million in Q3 2025.